ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Anebulo Pharmaceuticals, Inc. (ANEB) stock declined over -5.94%, trading at $0.95 on NASDAQ, down from the previous close of $1.01. The stock opened at $1.05, fluctuating between $0.95 and $1.05 in the recent session.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Employees | 2 |
Beta | -1.14 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | June |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep